Nurix Therapeutics (NRIX) Net Margin (2019 - 2025)
Nurix Therapeutics (NRIX) has disclosed Net Margin for 7 consecutive years, with 576.13% as the latest value for Q4 2025.
- On a quarterly basis, Net Margin fell 13538.0% to 576.13% in Q4 2025 year-over-year; TTM through Nov 2025 was 302.47%, a 5239.0% increase, with the full-year FY2025 number at 314.9%, up 3995.0% from a year prior.
- Net Margin was 576.13% for Q4 2025 at Nurix Therapeutics, up from 761.62% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 79.14% in Q2 2023 to a low of 761.62% in Q3 2025.
- A 5-year average of 383.31% and a median of 380.41% in 2024 define the central range for Net Margin.
- Peak YoY movement for Net Margin: surged 41196bps in 2023, then tumbled -37271bps in 2025.
- Nurix Therapeutics' Net Margin stood at 509.59% in 2021, then crashed by -35bps to 688.74% in 2022, then surged by 60bps to 276.77% in 2023, then plummeted by -59bps to 440.75% in 2024, then plummeted by -31bps to 576.13% in 2025.
- Per Business Quant, the three most recent readings for NRIX's Net Margin are 576.13% (Q4 2025), 761.62% (Q3 2025), and 98.66% (Q2 2025).